Allogeneic Stem Cell Transplant

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
60 patients (estimated)
Sponsors
University of Minnesota - Masonic Cancer Center
Tags
Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1917
NCT Identifier
NCT06412497

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.